Nov, 2024

U.S.A.
News / Corporate
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DOHC), a member of Heritage Provider...
Read More

Sep, 2024

U.S.A.
News / Corporate
Japan's Ministry of Health, Labour and Welfare Approves PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing...
Read More
U.S.A.
News / Corporate
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
- New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring - TOKYO, Sept. 18, 2024 /PRNewswire/ --...
Read More
U.S.A.
News / Corporate
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners
Read More
U.S.A.
News / Corporate
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
- Pooled analyses from two SKYLIGHT™ studies highlight impact on sleep disturbance and impairment, relationship between improvements in the frequency or severity of hot flashes and mood - Pooled...
Read More